Hepatocellular carcinoma: Clinical study of long-term survival and choice of treatment modalities

Table 3 Comparison of treatmentefficacy between the 5-year survival group and 10-year survival group for hepatocellular carcinoma

Characteristics	5-yr survival group	P value	10-yr survival group	P value	P value ​​between groups
AFP the first time before and after treatment (ng/mL)
Surgery		0.002		0.000
Before surgery	1020 (4596.63 ± 17193.11)		358 (7419.90 ± 18412.64)		0.049
After surgery	1020 (1133.25 ± 4530.36)		358 (1255.09 ± 4337.24)		0.070
TACE		0.039		0.002
Before TACE	496 (4510.68 ± 15115.73)		162 (2827.99 ± 9506.04)		0.446
After TACE	496 (1732.58 ± 7631.56)		162 (502.21 ± 1526.13)		0.711
Liver function the first time before and after treatment
Total bilirubin (mg/dL)		0.721		0.353
Before treatment	68.32 ± 58.98		19.63 ± 12.65		0.078
After treatment	67.22 ± 69.45		18.76 ± 11.56		0.120
AST (U/L)		0.983		0.730
Before treatment	51.99 ± 28.41		52.69 ± 40.86		0.137
After treatment	50.87 ± 27.50		52.42 ± 39.77		0.695
ALT (U/L)		0.104		0.262
Before treatment	52.46 ± 37.21		50.69 ± 53.10		0.291
After treatment	54.60 ± 42.26		51.16 ± 50.09		0.126
γ-glutamyltransferase (U/L)		0.366		0.017
Before treatment	19.30 ± 8.09		69.85 ± 93.75		0.122
After treatment	19.53 ± 8.32		58.79 ± 67.08		0.670
Time to first tumor recurrence or metastasis (d)		0.012		0.045
Surgery alone	90 (1031.36 ± 662.61)		38 (3246.38 ± 2047.29)		0.003
TACE alone	32 (675.64 ± 412.31)		12 (1882.77 ± 1324.08)		0.015
Surgery + TACE	225 (1012.00 ± 818.86)		70 (2778.30 ± 6296.35)		0.007
Surgery + TACE + RFA	90 (798.41 ± 492.01)		52 (2553.20 ± 1746.48)		0.016

RFA: Radiofrequency ablation; TACE: Transcatheter arterial chemoembolization; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase.